NCT06491446 2026-02-18
Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts
Antiva Biosciences
Phase 1/2 Active not recruiting
Antiva Biosciences
Qurasense
Verrica Pharmaceuticals Inc.
Novartis
Vaxart
Tamir Biotechnology, Inc.